APA (7th ed.) Citation

Diermayr, V., Tan, D., Ngoi, N. Y. L., Ng, M., Messersmith, W., Corr, B., . . . Koh, C. (2023). EP311/#691  Efficacy of the porcupine inhibitor ETC-1922159 (ETC-159) plus pembrolizumab in microsatellite stable (MSS) or proficient mismatch repair (PMMR) platinum resistant ovarian carcinomas (PROC). International journal of gynecological cancer, 33(Suppl 4), A205. https://doi.org/10.1136/ijgc-2023-IGCS.374

Chicago Style (17th ed.) Citation

Diermayr, Veronica, et al. "EP311/#691  Efficacy of the Porcupine Inhibitor ETC-1922159 (ETC-159) Plus Pembrolizumab in Microsatellite Stable (MSS) or Proficient Mismatch Repair (PMMR) Platinum Resistant Ovarian Carcinomas (PROC)." International Journal of Gynecological Cancer 33, no. Suppl 4 (2023): A205. https://doi.org/10.1136/ijgc-2023-IGCS.374.

MLA (9th ed.) Citation

Diermayr, Veronica, et al. "EP311/#691  Efficacy of the Porcupine Inhibitor ETC-1922159 (ETC-159) Plus Pembrolizumab in Microsatellite Stable (MSS) or Proficient Mismatch Repair (PMMR) Platinum Resistant Ovarian Carcinomas (PROC)." International Journal of Gynecological Cancer, vol. 33, no. Suppl 4, 2023, p. A205, https://doi.org/10.1136/ijgc-2023-IGCS.374.